利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.019 秒)

    Method for destroying retinal pigment epithelial cells
    1.
    发明授权
    Method for destroying retinal pigment epithelial cells 失效
    破坏视网膜色素上皮细胞的方法

    公开(公告)号：US6138680A

    公开(公告)日：2000-10-31

    申请号：US14492

    申请日：1998-01-28

    申请人： Randolph H. Bretton

    发明人： Randolph H. Bretton

    IPC分类号： A61K9/08 ,  A61K31/715 ,  A61K38/00 ,  A61K38/16 ,  A61K38/17 ,  A61K38/22 ,  A61K38/43 ,  A61K47/48 ,  A61P27/02 ,  A61P43/00 ,  C08B37/00 ,  A61B19/00 ,  A01N37/18 ,  A01N43/04 ,  A01N38/00

    CPC分类号： B82Y5/00 ,  A61K47/48315 ,  A61K47/48353

    摘要： A method for destroying retinal pigment epithelial cells in an eye in order to prevent the occurrence of proliferative vitreoretinopathy. A solution containing a basement membrane binding agent conjugated to a cytotoxic agent is introduced into the vitreous chamber. The solution is maintained in the vitreous chamber for a period of time sufficient to permit the basement membrane binding agent to bind to basement membranes lining the vitreous chamber. The solution is then removed from the vitreous chamber, whereby a portion of the basement membrane binding agent remains bonded to basement membranes within the vitreous chamber, thereby exposing retinal pigment epithelial cells disposed on the basement membrane to the cytotoxic agent.

    摘要翻译： 一种破坏视网膜色素上皮细胞的方法，以防止增生性玻璃体视网膜病变的发生。 将含有与细胞毒性剂缀合的基底膜结合剂的溶液引入玻璃体腔。 将溶液保持在玻璃体腔中足以允许基底膜结合剂与衬里玻璃体腔室的基底膜结合的时间。 然后将溶液从玻璃体腔中除去，由此基底膜结合剂的一部分保持结合到玻璃体腔内的基底膜，从而将设置在基底膜上的视网膜色素上皮细胞暴露于细胞毒性剂。

    Liquid growth hormone formulation and method of use
    4.
    发明授权
    Liquid growth hormone formulation and method of use 有权
    液体生长激素配方及使用方法

    公开(公告)号：US07662393B2

    公开(公告)日：2010-02-16

    申请号：US11578136

    申请日：2005-03-30

    申请人： Tudor Arvinte ,  Karnine Luet Kleiber

    发明人： Tudor Arvinte ,  Karnine Luet Kleiber

    IPC分类号： A61K38/27 ,  A01N38/00 ,  A61K38/25

    CPC分类号： A61K47/12 ,  A61K38/27 ,  A61K47/02 ,  A61K47/10 ,  A61K2300/00

    摘要： The invention relates to a liquid formulation comprising a growth hormone or a substance, which stimulates release or potentiates the activity of endogenous hGH; a polyethylene-polypropylene glycol; a citrate/phosphate buffer, an alkali metal salt and an alkaline earth metal salt or a pseudo alkaline earth metal salt, and to a process of preparation thereof.

    摘要翻译： 本发明涉及包含生长激素或物质的液体制剂，其刺激释放或增强内源性hGH的活性; 聚乙烯 - 聚丙二醇; 柠檬酸盐/磷酸盐缓冲液，碱金属盐和碱土金属盐或假碱土金属盐，及其制备方法。

    Decellularized tissue engineered constructs and tissues
    6.
    发明授权
    Decellularized tissue engineered constructs and tissues 有权
    脱细胞组织工程构建体和组织

    公开(公告)号：US06962814B2

    公开(公告)日：2005-11-08

    申请号：US09931506

    申请日：2001-08-16

    申请人： Shannon Mitchell ,  Jennifer Koh ,  Vikas Prabhakar ,  Laura Niklason

    发明人： Shannon Mitchell ,  Jennifer Koh ,  Vikas Prabhakar ,  Laura Niklason

    IPC分类号： A61L27/38 ,  C12N5/00 ,  A61F2/02 ,  A61K48/00 ,  C12P21/00 ,  A01N38/00

    CPC分类号： A61L27/3839 ,  A61L27/3691 ,  C12N5/0068 ,  C12N2533/30 ,  C12N2533/40 ,  C12N2533/90

    摘要： New methods for producing tissue engineered constructs and engineered native tissues are disclosed. The methods include producing a tissue engineered construct by growing cells in vitro on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed. The decellularized construct can be used for further tissue engineering, which may include seeding the construct with cells obtained from the intended recipient of the construct. During any of the growth phases required for production of the construct, the developing construct may be subjected to various tissue engineering steps such as application of mechanical stimuli including pulsatile forces. The methods also include producing an engineered native tissue by harvesting tissue from an animal or human, performing one or more tissue engineering steps on the tissue, and subjecting the tissue to decellularization. The decellularized, engineered native tissue may then be subjected to further tissue engineering steps.

    摘要翻译： 公开了用于生产组织工程化构建体和工程化天然组织的新方法。 所述方法包括通过在基质上体外培养细胞产生组织工程化构建体，然后使构建体脱细胞化以产生主要由细胞外基质组分组成的脱细胞结构。 该结构可以立即使用或存储直到需要。 脱细胞化构建体可用于进一步的组织工程，其可以包括使用从构建体的预期接受者获得的细胞接种构建体。 在制造结构所需的任何生长阶段期间，显影构件可以经受各种组织工程步骤，例如施加包括脉动力的机械刺激。 所述方法还包括通过从动物或人收集组织来产生工程化的天然组织，在组织上执行一个或多个组织工程步骤，以及对组织进行脱细胞化。 然后可以将脱细胞化的工程化天然组织进行进一步的组织工程步骤。

    Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
    9.
    发明授权
    Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies 失效
    与OB蛋白和OB抗体调节能量动员相关的诊断和治疗方法

    公开(公告)号：US07067472B1

    公开(公告)日：2006-06-27

    申请号：US09194889

    申请日：1997-06-04

    申请人： Lili Feng ,  Shizhong Chen ,  Yiyang Xia

    发明人： Lili Feng ,  Shizhong Chen ,  Yiyang Xia

    IPC分类号： A01N38/00 ,  A61K39/00 ,  C07K14/00

    CPC分类号： C07K14/5759

    摘要： Compositions comprising OB-R agonists and methods of treatment for conditions such as systemic inflammatory response syndrome are provided. One suitable OB-R agonist ligand is recombinant human OB protein, also known as leptin. Also provided are methods and compositions for the treatment of obesity and OB resistance. Assay methods and kits relating to these conditions are also included.

    摘要翻译： 提供了包含OB-R激动剂的组合物和治疗诸如全身炎症反应综合征的病症的方法。 一种合适的OB-R激动剂配体是重组人OB蛋白，也称为瘦蛋白。 还提供了用于治疗肥胖症和耐药性的方法和组合物。 还包括与这些条件相关的测定方法和试剂盒。